NRF2 activation in cancer and overview of NRF2 small molecule inhibitors

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Archives of pharmacal research

• Publication date

  2025-08-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s12272-025-01557-xPMID 40815486
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• NRF2 supports non-small cell lung cancer growth independently of CBP/p300-enhanced glutathione synthesis

  2025cited by this paper
• Identification of narciclasine as a novel NRF2 inhibitor

  2025cited by this paper
• E3 ubiquitin ligase SYVN1 as a promising therapeutic target for diverse human diseases.

  2025cited by this paper
• Regulating Nrf2 activity: ubiquitin ligases and signaling molecules in redox homeostasis.

  2025cited by this paper
• NRF2 Signaling Pathway in Chemo/Radio/Immuno-Therapy Resistance of Lung Cancer: Looking Beyond the Tip of the Iceberg.

  2024cited by this paper
• The Multifaceted Roles of NRF2 in Cancer: Friend or Foe?

  2024cited by this paper
• NRF2 is a spatiotemporal metabolic hub essential for the polyfunctionality of Th2 cells

  2024cited by this paper
• Endogenously produced itaconate negatively regulates innate-driven cytokine production and drives global ubiquitination in human macrophages.

  2024cited by this paper
• Glutathione synthesis in the mouse liver supports lipid abundance through NRF2 repression

  2024cited by this paper
• Triptolide Promotes Ferroptosis in Cervical Cancer Cell via NRF2/xCT/GPX4

  2024cited by this paper
• Differential squamous cell fates elicited by NRF2 gain of function versus KEAP1 loss of function.

  2024cited by this paper
• Imaging NRF2 activation in non-small cell lung cancer with positron emission tomography

  2024cited by this paper
• Kelch-like ECH-associated Protein 1/Nuclear Factor Erythroid 2-related Factor 2 Pathway and Its Interplay with Oncogenes in Lung Tumorigenesis

  2024cited by this paper
• Embracing cancer complexity: Hallmarks of systemic disease.

  2024cited by this paper
• Biomarkers of NRF2 signalling: Current status and future challenges

  2024cited by this paper
• New insights into protein–protein interaction modulators in drug discovery and therapeutic advance

  2024cited by this paper
• Ironing out the details of ferroptosis

  2024cited by this paper
• New insights into crosstalk between Nrf2 pathway and ferroptosis in lung disease

  2024cited by this paper
• Targeting the NRF2 pathway for disease modification in neurodegenerative diseases: mechanisms and therapeutic implications

  2024cited by this paper
• NRF2 signaling and amino acid metabolism in cancer

  2024cited by this paper
• Ferroptosis: when metabolism meets cell death.

  2024cited by this paper
• WDR23 mediates NRF2 proteostasis and cytoprotective capacity in the hippocampus.

  2024cited by this paper
• Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer

  2024cited by this paper
• PPIA dictates NRF2 stability to promote lung cancer progression

  2024cited by this paper
• USP13 facilitates a ferroptosis-to-autophagy switch by activation of the NFE2L2/NRF2-SQSTM1/p62-KEAP1 axis dependent on the KRAS signaling pathway

  2024influential reference
• Hypoxia, oxidative stress, and the interplay of HIFs and NRF2 signaling in cancer

  2024cited by this paper
• High Expression of NRF2 and Low Expression of KEAP1 Predict Worse Survival in Patients With Operable Triple-Negative Breast Cancer

  2023cited by this paper
• A Point Mutation at C151 of Keap1 of Mice Abrogates NRF2 Signaling, Cytoprotection in Vitro, and Hepatoprotection in Vivo by Bardoxolone Methyl (CDDO-Me)

  2023cited by this paper
• Immunoediting of KEAP1-NRF2 mutant tumours is required to circumvent NRF2-mediated immune surveillance

  2023cited by this paper
• NRF2, a Superstar of Ferroptosis

  2023cited by this paper
• Battles against aberrant KEAP1-NRF2 signaling in lung cancer: intertwined metabolic and immune networks

  2023cited by this paper
• NRF2 signalling in cytoprotection and metabolism

  2023cited by this paper
• ARE-PROTACs Enable Co-degradation of an Nrf2-MafG Heterodimer.

  2023cited by this paper
• Endoplasmic reticulum stress: molecular mechanism and therapeutic targets

  2023cited by this paper
• AKT activation because of PTEN loss upregulates xCT via GSK3β/NRF2, leading to inhibition of ferroptosis in PTEN-mutant tumor cells

  2023cited by this paper
• DPP9 Stabilizes NRF2 to Suppress Ferroptosis and Induce Sorafenib Resistance in Clear Cell Renal Cell Carcinoma.

  2023cited by this paper
• Small molecule and peptide inhibitors of βTrCP and the βTrCP–NRF2 protein–protein interaction

  2023cited by this paper
• NRF2 signaling pathway and telomere length in aging and age-related diseases

  2023cited by this paper
• Fumarate hydratase (FH) and cancer: a paradigm of oncometabolism

  2023cited by this paper
• Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials

  2023cited by this paper
• Eriodictyol regulated ferroptosis, mitochondrial dysfunction, and cell viability via Nrf2/HO‐1/NQO1 signaling pathway in ovarian cancer cells

  2023cited by this paper
• Stapled Peptides as Direct Inhibitors of Nrf2-sMAF Transcription Factors

  2023cited by this paper
• WDR23 mediates NRF2 proteostasis and cytoprotective capacity in the hippocampus

  2023cited by this paper
• The KEAP1-NRF2 pathway: Targets for therapy and role in cancer

  2023cited by this paper
• The evolution of lung cancer and impact of subclonal selection in TRACERx

  2023cited by this paper
• A NRF2 inhibitor selectively sensitizes KEAP1 mutant tumor cells to cisplatin and gefitinib by restoring NRF2-inhibitory function of KEAP1 mutants.

  2023cited by this paper
• Genomic–transcriptomic evolution in lung cancer and metastasis

  2023cited by this paper
• The Multi-Faceted Consequences of NRF2 Activation throughout Carcinogenesis

  2023cited by this paper
• Exploring structural effects in a new class of NRF2 inhibitors.

  2023influential reference
• Advances and challenges in therapeutic targeting of NRF2.

  2023cited by this paper
• Distinct Nrf2 Signaling Thresholds Mediate Lung Tumor Initiation and Progression

  2023cited by this paper
• Tumor-immune microenvironment and NRF2 associate with clinical efficacy of PD-1 blockade combined with chemotherapy in lung squamous cell carcinoma

  2023cited by this paper
• Nrf2, A Target for Precision Oncology in Cancer Prognosis and Treatment

  2023cited by this paper
• NRF2 activation induces NADH-reductive stress, providing a metabolic vulnerability in lung cancer.

  2023cited by this paper
• Molecular Basis of the KEAP1-NRF2 Signaling Pathway

  2023cited by this paper
• Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies

  2023cited by this paper
• NRF2 controls iron homeostasis and ferroptosis through HERC2 and VAMP8

  2023cited by this paper
• USP13 deubiquitinates p62/SQSTM1 to induce autophagy and Nrf2 release for activating antioxidant response genes.

  2023cited by this paper
• Therapeutic Administration of Oxcarbazepine Saves Cerebellar Purkinje Cells from Ischemia and Reperfusion Injury Induced by Cardiac Arrest through Attenuation of Oxidative Stress

  2022cited by this paper
• Design and synthesis of Nrf2-derived hydrocarbon stapled peptides for the disruption of protein-DNA-interactions

  2022cited by this paper
• KEAP1‐NRF2 protein–protein interaction inhibitors: Design, pharmacological properties and therapeutic potential

  2022cited by this paper
• KEAP1 -Mutant NSCLC: The Catastrophic Failure of a Cell-Protecting Hub

  2022cited by this paper
• Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug

  2022cited by this paper
• Halofuginone micelle nanoparticles eradicate Nrf2-activated lung adenocarcinoma without systemic toxicity.

  2022cited by this paper
• Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathway

  2022cited by this paper
• The β-TrCP-Mediated Pathway Cooperates with the Keap1-Mediated Pathway in Nrf2 Degradation In Vivo

  2022cited by this paper
• Deubiquitinase-targeting chimeras for targeted protein stabilization

  2022cited by this paper
• OTUD1 deubiquitinase regulates NF-κB- and KEAP1-mediated inflammatory responses and reactive oxygen species-associated cell death pathways

  2022cited by this paper
• Novel NRF2‐activated cancer treatments utilizing synthetic lethality

  2022cited by this paper
• Significance of NRF2 in physiological and pathological conditions an comprehensive review.

  2022cited by this paper
• BAP1 Downregulates NRF2 Target Genes and Exerts Anti-Tumorigenic Effects by Deubiquitinating KEAP1 in Lung Adenocarcinoma

  2022cited by this paper
• Small molecule screen identifies pyrimethamine as an inhibitor of NRF2-driven esophageal hyperplasia

  2022cited by this paper
• Concise Review: Gene of The Month KEAP1-mutant non-small cell lung cancer: the catastrophic failure of a cell-protecting hub.

  2022cited by this paper
• Inhibitors

  2021cited by this paper
• KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance

  2021cited by this paper
• Triptolide Downregulates the Expression of NRF2 Target Genes by Increasing Cytoplasmic Localization of NRF2 in A549 Cells

  2021cited by this paper
• Discovery and characterization of novel peptide inhibitors of the NRF2/MAFG/DNA ternary complex for the treatment of cancer.

  2021cited by this paper
• A Novel Nrf2 Pathway Inhibitor Sensitizes Keap1-Mutant Lung Cancer Cells to Chemotherapy

  2021cited by this paper
• Molecular basis for the disruption of Keap1–Nrf2 interaction via Hinge & Latch mechanism

  2021cited by this paper
• NRF2-pathway mutations predict radioresistance in non-small cell lung cancer

  2021cited by this paper
• A Step toward NRF2‐DNA Interaction Inhibitors by Fragment‐Based NMR Methods

  2021cited by this paper
• Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathway

  2021cited by this paper
• Activation of the NRF2 antioxidant program sensitizes tumors to G6PD inhibition

  2021cited by this paper
• The deubiquitinase USP11 regulates cell proliferation and ferroptotic cell death via stabilization of NRF2 USP11 deubiquitinates and stabilizes NRF2

  2021cited by this paper
• Extracellular vesicles derived from melatonin‐preconditioned mesenchymal stem cells containing USP29 repair traumatic spinal cord injury by stabilizing NRF2

  2021cited by this paper
• NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes

  2020cited by this paper
• NRF2-Dependent Bioactivation of Mitomycin C as a Novel Strategy To Target KEAP1-NRF2 Pathway Activation in Human Cancer

  2020cited by this paper
• Metabolic features of cancer cells in NRF2 addiction status

  2020cited by this paper
• Emerging role of NRF2 in ROS-mediated tumor chemoresistance.

  2020cited by this paper
• The potential impact of trigonelline loaded micelles on Nrf2 suppression to overcome oxaliplatin resistance in colon cancer cells

  2020cited by this paper
• Trigonelline inhibits Nrf2 via EGFR signalling pathway and augments efficacy of Cisplatin and Etoposide in NSCLC cells.

  2020cited by this paper
• Ailanthone: A novel potential drug for treating human cancer

  2020cited by this paper
• Ailanthone increases oxidative stress in CDDP-resistant ovarian and bladder cancer cells by inhibiting of Nrf2 and YAP expression through a post-translational mechanism.

  2020cited by this paper
• Regulation of NRF2 by Na+/K+-ATPase: implication of tyrosine phosphorylation of Src

  2020cited by this paper
• Geldanamycin-Derived HSP90 Inhibitors Are Synthetic Lethal with NRF2

  2020cited by this paper
• Dexamethasone enhances the antitumor efficacy of Gemcitabine by glucocorticoid receptor signaling

  2020cited by this paper
• Artemisinin-Derivative-NHC-gold(I)-Hybrid with enhanced cytotoxic activity through inhibiting NRF2 transcriptional activity.

  2020cited by this paper
• Prey for the Proteasome: Targeted Protein Degradation—A Medicinal Chemist's Perspective

  2020cited by this paper
• Kaempferol inhibits Nrf2 signalling pathway via downregulation of Nrf2 mRNA and induces apoptosis in NSCLC cells.

  2020cited by this paper
• STK11/LKB1 Mutations in NSCLC Are Associated with KEAP1/NRF2-Dependent Radiotherapy Resistance Targetable by Glutaminase Inhibition

  2020cited by this paper

• Research Progress on Ferroptosis-Related Pathways and the Pathogenic Mechanisms of Epilepsy

  2025cites this paper